What question did this study set out to answer?

To examine the distinct biological and logistical barriers hindering CAR T-cell therapy in T-cell and myeloid leukemias and evaluate emerging engineering strategies designed to overcome them.

December 2, 2025HematologyOpen Access

Have CARs stalled for non–B-cell malignancies? Where are we, and where are we going?

View Full Paper

Ask AI

Bookmark

Authors

SSSara Sillbert ALAdam J. Lamble

Discussion

Member takes

Overview

Case-based review uncovers biological barriers and emerging bioengineering strategies for CAR T-cell therapies in T-cell and myeloid leukemias, highlighting paths to overcome treatment resistance.

Key Points

To examine the distinct biological and logistical barriers hindering CAR T-cell therapy in T-cell and myeloid leukemias and evaluate emerging engineering strategies designed to overcome them.
Reviewed translational and clinical progress of CAR T-cell designs in non–B-cell hematologic malignancies, structured around a real-world clinical case.
Analyzed early-phase clinical trial data for CD5 and CD7 targets alongside advanced bioengineering approaches, including gene editing, logic gating, and allogeneic platforms.
Early-phase clinical trials targeting CD5 and CD7 show encouraging response rates in T-cell acute lymphoblastic leukemia, though fratricide, profound T-cell aplasia, and dependence on consolidative stem cell transplantation persist.
CAR T-cell efficacy in acute myeloid leukemia remains limited by antigen non-specificity and an immunosuppressive microenvironment, prompting multiantigen targeting, epitope editing, and off-the-shelf allogeneic platforms.

Cite This Study

Sillbert et al. (2025) studied this question.

synapsesocial.com/papers/6a123205ea48cb855a345cf8 https://doi.org/10.1182/hematology.2025000733

View Full Paper

Ask AI

Bookmark

December 2, 2025HematologyOpen Access

Have CARs stalled for non–B-cell malignancies? Where are we, and where are we going?

View Full Paper

Ask AI

Bookmark

Authors

SSSara Sillbert ALAdam J. Lamble

Discussion

Member takes

Overview

Case-based review uncovers biological barriers and emerging bioengineering strategies for CAR T-cell therapies in T-cell and myeloid leukemias, highlighting paths to overcome treatment resistance.

Key Points

To examine the distinct biological and logistical barriers hindering CAR T-cell therapy in T-cell and myeloid leukemias and evaluate emerging engineering strategies designed to overcome them.
Reviewed translational and clinical progress of CAR T-cell designs in non–B-cell hematologic malignancies, structured around a real-world clinical case.
Analyzed early-phase clinical trial data for CD5 and CD7 targets alongside advanced bioengineering approaches, including gene editing, logic gating, and allogeneic platforms.
Early-phase clinical trials targeting CD5 and CD7 show encouraging response rates in T-cell acute lymphoblastic leukemia, though fratricide, profound T-cell aplasia, and dependence on consolidative stem cell transplantation persist.
CAR T-cell efficacy in acute myeloid leukemia remains limited by antigen non-specificity and an immunosuppressive microenvironment, prompting multiantigen targeting, epitope editing, and off-the-shelf allogeneic platforms.

Cite This Study

Sillbert et al. (2025) studied this question.

synapsesocial.com/papers/6a123205ea48cb855a345cf8 https://doi.org/10.1182/hematology.2025000733

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark